Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2GPD2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Metformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL1766280 | 0.97 | LMNA (0.36) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL8944 | 0.97 | — | — | |
| Metformin SCHEMBL1333960 | 0.94 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL22127017 | 0.94 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL18953625 | 0.94 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL433864 | 0.94 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL4421557 | 0.94 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL1560020 | 0.94 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL15268394 | 0.94 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL292820 | 0.94 | LMNA (0.35) | LMNADPP4ADRA1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426746-B2 | Methods of treating developmental disorders with biguanides | OVID THERAPEUTICS INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2822579-B1 | COMPOSITIONS FOR REGULATING ENERGY METABOLISM | NUSIRT SCIENCES INC (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3484452-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH BIGUANIDES | Ovid Therapeutics, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20190046480-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH BIGUANIDES | OVID THERAPEUTICS INC. | 2019-02-14 | — | — | US | disclosed |
| US-10123979-B2 | Methods of treating developmental disorders with biguanides | OVID THERAPEUTICS INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-9901573-B2 | Compositions, methods, and kits for regulating energy metabolism | NUSIRT SCIENCES, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20180050001-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH BIGUANIDES | OVID THERAPEUTICS INC. | 2018-02-22 | — | — | US | disclosed |
| WO-2018035408-A1 | METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH BIGUANIDES | OVID THERAPEUTICS INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20170368045-A1 | COMPOSITIONS, METHODS, AND KITS FOR REGULATING METABOLISM | NUSIRT SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9713609-B2 | Compositions, methods, and kits for regulating energy metabolism | NUSIRT SCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170000777-A1 | COMPOSITIONS, METHODS, AND KITS FOR REGULATING ENERGY METABOLISM | NUSIRT SCIENCES, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9408410-B2 | Compositions, methods, and kits for regulating energy metabolism | NUSIRT SCIENCES, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160113317-A1 | COMPOSITIONS, METHODS, AND KITS FOR REGULATING ENERGY METABOLISM | NUSIRT SCIENCES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9198454-B2 | Compositions, methods, and kits for regulating energy metabolism | NUSIRT SCIENCES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2822579-A1 | COMPOSITIONS, METHODS, AND KITS FOR REGULATING ENERGY METABOLISM | Nusirt Sciences, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20140044783-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A THIAZOLIDINEDIONE | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-13 | — | — | US | disclosed |
| US-20130237605-A1 | COMPOSITIONS, METHODS, AND KITS FOR REGULATING ENERGY METABOLISM | NUSIRT SCIENCES, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2013134736-A1 | COMPOSITIONS, METHODS, AND KITS FOR REGULATING ENERGY METABOLISM | NUSIRT SCIENCES, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-2441442-A1 | A pharmaceutical composition comprising a thiazolidinedione | LEK Pharmaceuticals d.d. (SI) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012045859-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A THIAZOLIDINEDIONE | LEK PHARMACEUTICALS D.D. (SI) | 2012-04-12 | — | — | WO | disclosed |